Operator Good day. Thank you for standing by, and welcome to the G1 Therapeutics Second Quarter 2021 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] I would now like to turn the conference over to your host, Mr. Will Roberts. Please go ahead, sir. William Roberts -- Vice President of Investor Relations & Corporate Communications Thank you, Sarah. Good afternoon, everyone, and welcome to the G1 conference call to discuss our second quarter 2021 financial results and business update. The press release on these financial results was issued after market closed this afternoon and can be found in the News section of our corporate website, G1therapeutics.com. On this call, the team will provide a business overview of the second quarter of 2021, including an update on our launch progress in that period with COSELA which was approved by the U.S. Food and Drug Administration on February 12, 2021, to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer or ES-SCLC and became available in the channel in early March of 2021. A question-and-answer session will follow the prepared remarks.